Cipla logs Q1 PAT of Rs715cr rising by 24% yoy on robust revenue

Consolidated revenue from operations stood at Rs5,504cr in the quarter under review increasing by 27% yoy and 19% qoq.

Aug 06, 2021 08:08 IST India Infoline News Service

Cipla
Pharma-major, Cipla consolidated net profit of Rs715cr for the quarter ending June 2021 (Q1FY22) rising by 24% yoy and a whopping 73% qoq. On Friday, Cipla stock will be in focus after Q1 earnings.

Consolidated revenue from operations stood at Rs5,504cr in the quarter under review increasing by 27% yoy and 19% qoq.

Key highlights of the quarter are:
  • One India: Overall business grew by 68% YoY with strong volume traction in core therapies and Covid-19 portfolio contribution
  • SAGA: Continued market-beating growth in South Africa private business; SAGA grew 13% YoY in USD terms
  • US business: Reported USD 141Mn revenue and 5% YoY growth led by continued expansion in market share of Albuterol
  • Quality Focus: Working with USFDA on Goa plant observations; Infrastructure for virtual audit in place
  • R&D investments stand at INR 264 crore; the Absolute trajectory of R&D spends on track
  • Continued healthy net cash positive position led by operating profitability and prudent working capital management
Umang Vohra MD and Global CEO, Cipla said, "At Cipla, we feel proud to have contributed extensively to the fight against covid-19 amid the second wave by ensuring continuous supply of life-saving medicines. I am pleased to see the robust demand led traction in core therapies across our branded markets and continued cost control leading to 27% revenue growth and 24.5% EBITDA margin for the quarter. In India, we maintained our market-beating performance as core therapies responded to demand triggers along with support from the covid portfolio during the second wave."

Vohra added, " I am delighted to witness the continued unlocking of our respiratory franchise in the US with market share expansion in Albuterol and strengthening of the portfolio with Arformoterol launch. Our South Africa private business continues to outperform the market. Our investments in creating a differentiated API portfolio have helped drive growth in the quarter."

On the previous day, Cipla stock finished at Rs945.20 per piece up 0.6% on Sensex.

Related Story

Open Free Demat Account (Rs699)